Opthea Ltd
Company Profile
Business description
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
Contact
650 Chapel Street
Level 4, Suite 0403
South YarraVIC3141
AUST: +61 398260399
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
34
Stocks News & Analysis
stocks
Strong finish to the year for overvalued ASX share
stocks
Our three most overvalued ASX shares
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,072.80 | 47.70 | -0.52% |
| CAC 40 | 7,734.84 | 60.06 | 0.78% |
| DAX 40 | 23,807.13 | 210.15 | 0.89% |
| Dow JONES (US) | 45,514.95 | 114.09 | 0.25% |
| FTSE 100 | 9,221.44 | 13.23 | 0.14% |
| HKSE | 25,711.77 | 77.86 | 0.30% |
| NASDAQ | 21,798.70 | 98.31 | 0.45% |
| Nikkei 225 | 43,900.13 | 256.32 | 0.59% |
| NZX 50 Index | 13,241.47 | 39.67 | -0.30% |
| S&P 500 | 6,495.15 | 13.65 | 0.21% |
| S&P/ASX 200 | 8,795.20 | 45.70 | -0.52% |
| SSE Composite Index | 3,818.37 | 8.47 | -0.22% |